Forest, Almirall Drug Wins Backing of FDA Panel Advisers
This article is for subscribers only.
Forest Laboratories Inc. and Almirall SA’s experimental drug to help patients with a chronic lung disease breathe more easily should be approved, a panel of U.S. regulatory advisers said.
The panel voted 12-2 today to recommend approval of aclidinium bromide, a twice-daily medication that reduces complications stemming from chronic obstructive pulmonary disease. The condition, typically caused by smoking, affects 12 million Americans and is the third-leading cause of death nationwide, according to the National Institutes of Health.